Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers

British Journal of Pharmacology

Volumn 129, Issue 6, 2000, Pages 1235-1243

  Soldner, Andrea ^a   Benet, Leslie Z ^a   Mutschler, Ernst ^b   Christians, Uwe ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Angiotensin II antagonists; Caco 2 cells; Intestinal drug transporters; MDCK MDR1 cells; P glycoprotein

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CARBOXYLIC ACID; CYCLOSPORIN; GLYCOPROTEIN P; LOSARTAN; VINBLASTINE;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034061961     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703150     Document Type: Article

References (36)

1. ARTURSSON, P. & KARLSSON, J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun., 175, 880-885.
2. AUNGST, B.J. (1993). Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci., 82, 979-987.
3. BENET, L.Z., WU, C.-Y., HEBERT, M.F. & WACHER, V.J. (1996). Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Release, 39, 139-143.
4. BORST, P., KOOL. M. & EVERS, R. (1997). Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Cancer Biol., 8, 205-213.
5. CAVET, M.E., WEST, M. & SIMMONS, N.L. (1996). Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol., 118, 1389-1396.
6. CAVET, M.E., WEST, M. & SIMMONS, N.L. (1997). Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol, 121, 1567-1578.
7. DEELEY, R.G. & COLE, S.P.C. (1997). Function, evolution and structure of multidrug resistance protein (MRP). Cancer Biol., 8, 193-204.
8. EVERS, R., KOOL, M., VAN DEEMTER, L., JANSSEN, H., CALAFAT, J., OOMEN, L.C.J.M., PAULUSMA, C.C., OUDE ELFERINK, R.P.J., BAAS, F., SCHINKEL, A.H. & BORST, P. (1998). Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest., 101, 1310-1319.
9. EVERS, R., ZAMAN, G.J.R., VAN DEEMTER, L., JANSEN, H., CALAFAT, J., OOMEN, L.C.J.M., OUDE ELFERINK, R.P.J., BORST, P. & SCHINKEL, A.H. (1996). Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest., 97, 1211-1218.
10. FORD, J.M. & HAIT, W.N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199.
11. GAN, L.S., MOSELEY, M.A., KHOSLA, B., AUGUSTIJNS, P.F., BRADSHAW, T.P., HENDREN, R.W. & THAKKER, D.R. (1996). CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos., 24, 344-349.
12. GERMANN, U.A., FORD, P.J., SHLYAKHTER, D., MASON, V.S. & HARDING, M.W. (1997). Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anti Cancer Drugs, 8, 141-155.
13. HUNTER, J., HIRST, B.H. & SIMMONS, N.L. (1993a). Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res., 10, 743-749.
14. HUNTER, J., HIRST, B.H. & SIMMONS, N.L. (1993b). Transepithelial secretion, cellular accumulation and cytotoxicity of vinblastine in defined MDCK cell strains. Biochim. Biophys. Acta, 1179, 1-10.
15. HUNTER, J., JEPSON, M.A., TSURUO, T., SIMMONS, N. & HIRST, B.H. (1993c). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem., 268, 14991-14997.
16. KIM, W.J., KAKEHI, Y., HIRAI, M., ARAO, S., HIAI, H., FUKUMOTO, M. & YOSHIDA, O. (1995). Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line. Jpn. J. Cancer Res., 86, 969-977.
17. KOLARS, J.C., LOWN, K.S., SCHMIEDLIN, R.P., GHOSH, M., FANG, C, WRIGHTON, S.A., MERION, R.M. & WATKINS, P.B. (1994). CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4, 247-259.
18. LAMPEN, A., CHRISTIANS, U., GONSCHIOR, A.K., BADER, A., HACKBARTH, I., VON ENGELHARDT, W. & SEWING, K.F. (1996). Metabolism of the macrolide immunosuppressant tacrolimus by the pig mucosa in the Ussing chamber. Br. J. Pharmacol., 117, 1730-1734.
19. LAMPEN, A., ZHANG, Y., HACKBARTH, I., BENET, L.Z., SEWING, K.F. & CHRISTIANS, U. (1998). Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J. Pharmacol. Exp. Ther., 285, 1104-1112.
20. LANG, V.B., LANGGUTH, P., OTTIGER, C., WUNDERLI-ALLEN-SPACH, H., ROGNAN, D., ROTHEN-RUTISHAUSER, B., PERRIARD, J.C., LANG, S., BIBER, J. & MERKLE, H.P. (1997). Structure-permeation relations of Met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J. Pharm. Sci., 86, 846-853.
21. LIN, J.H., CHIBA, M. & BAILLIE, T.A. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 51, 135-158.
22. LIU, Y., HUANG, L., HOFFMAN, T., GOSLAND, M. & VORE, M. (1996). MDR1 substrates-modulators protect against β-estradiol-17-β-D-glucuronide cholestasis in rat liver. Cancer Res., 56, 4992-4997.
23. LO, M.-W., GOLDBERG, M.R., MCCREA, J.B., LU, H., FURTEK, C.I. & BJORNSSON, T.D. (1995). Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans. Clin. Pharmacol. Ther., 58, 641-649.
24. MAKHEY, V.D., GUO, A., NORRIS, D.A., HU, P., YAN, J. & SINKO, P.J. (1998). Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res., 15, 1160-1167.
25. NIES, A.T., CANTZ, T., BROM, M., LEIER, I. & KEPPLER, D. (1998). Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B. Hepatology, 28, 1332-1340.
26. NORRIS, D.A., GUO, A., MAKHEY, V.D. & SINKO, P.J. (1997). Functional expression and immunoquantitation of multidrug resistance (MDR) efflux pumps, Pgp and MRP, in Caco-2 cells as a function of passage number. Pharm. Res., 14, S669-S670.
27. PASTAN, I., GOTTESMAN, M.M., UEDA, K., LOVELACE, E., RUTHERFORD, A.V. & WILLINGHAM, M.C. (1988). A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. U.S.A., 85, 4486-4490.
28. PINTO, M., ROBINE-LEON, S., APPAY, M.-D., KEDINGER, M., TRIADOU, N., DUSSAULX, E., LACROIX, B., SIMON-ASSMANN, P., HAFFEN, K., FOGH, J. & ZWEIBAUM, A. (1983). Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell, 47, 323-330.
29. PRUEKSARITANONT, T., DELUNA, P., GORHAM, L.M., MA, B., COHN, D., PANG, J., XU, X., LEUNG, K. & LIN, J.H. (1998). In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Drug Metab. Dispos., 26, 520-527.
30. RENES, J., DE VRIES, E.G.E., NIENHUIS, E.F., JANSEN, P.L.M. & MÜLLER, M. (1999). ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharm., 126, 681-688.
31. STEARNS, R.A., CHAKRAVARTY, P.K., CHEN, R. & CHIU, S.H.-L. (1995). Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos., 23, 207-215.
32. STEARNS, R.A., MILLER, R.R., DOSS, G.A., CHAKRAVARTY, P.K., ROSEGAY, A., GATTO, G.J. & CHIU, S.H.-L. (1992). The metabolism of DUP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey and human liver slices. Drug Metab. Dispos., 20, 281-287.
33. TIMMERMANS, P.B.M.W.M., WONG, P.C., CHIU, A.T., HERBLIN, W.F., BENFIELD, P., CARINI, D.J., LEE, R.J., WEXLER, R.R., SAYE, J.A.M. & SMITH, R.D. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev., 45, 205-251.
34. WACHER, V.J., WU, C.Y. & BENET, L.Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13, 129-134.
35. WONG, P.C., PRICE, W.A., CHIU, A.T., DUNCIA, J.V., CARINI, D.J., WEXLER, R.R., JOHNSON, A.L. & TIMMERMANS, P.B.M.W.M. (1990). Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: an active metabolite of DUP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 255, 211-217.
36. ZHANG, Y. & BENET, LZ. (1998). Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDRI-MDCK and Caco-2 cell monolayers. Pharm. Res., 15, 1520-1524.